As of 2024-12-14, the Intrinsic Value of Castle Biosciences Inc (CSTL) is
1.08 USD. This CSTL valuation is based on the model Peter Lynch Fair Value.
With the current market price of 29.12 USD, the upside of Castle Biosciences Inc is
-96.28%.
CSTL Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(446.37) - (113.29) |
(178.80) |
-714.0% |
| DCF (Growth 10y) |
(173.98) - (658.76) |
(269.75) |
-1026.3% |
| DCF (EBITDA 5y) |
(55.29) - (63.92) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(100.39) - (121.37) |
(1,234.50) |
-123450.0% |
| Fair Value |
1.08 - 1.08 |
1.08 |
-96.28% |
| P/E |
4.59 - 8.08 |
5.60 |
-80.8% |
| EV/EBITDA |
7.21 - 8.05 |
7.56 |
-74.0% |
| EPV |
(21.92) - (29.59) |
(25.75) |
-188.4% |
| DDM - Stable |
2.92 - 15.36 |
9.14 |
-68.6% |
| DDM - Multi |
(64.36) - (261.60) |
(103.13) |
-454.2% |
CSTL Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
815.65 |
| Beta |
0.40 |
| Outstanding shares (mil) |
28.01 |
| Enterprise Value (mil) |
731.00 |
| Market risk premium |
4.60% |
| Cost of Equity |
7.23% |
| Cost of Debt |
7.00% |
| WACC |
7.23% |